PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Administration, Intravaginal”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 451 records · Page 25Linked to original sources
PubMedDate not supplied

Human synthetic peptide vaccine for contraception targeting sperm.

A vaccine targeting sperm is an interesting approach to contraception. The acceptability of a sperm antigen for contraceptive vaccine development is contingent upon its sperm-specificity, surface expression for antibody binding, and involvement in fertilization. Sperm-zona pellucida (ZP) binding is a pivotal step and constitutes an attractive site for immunointerception. Using phage display technology, we have identified a novel dodecamer peptide sequence, designated as YLP(12), that is present on sperm, and is involved in ZP binding and sperm capacitation/acrosome reaction in man/mouse. Extensive search in the human and mouse genome sequence databases did not indicate a complete identity with the YLP(12) nucleotide sequence. It is peptide mimetic with sperm receptor carbohydrate mimicking action that is involved in oocyte binding. The sperm-specific YLP(12) sequence is also involved in involuntary immunoinfertility in men, indicating its autoantigenicity, sperm-specificity, and involvement in fertility/infertility in humans. Vaccination of female animals with synthetic YLP(12) peptide causes a long-term reversible contraception by raising a sperm-specific immune response. The contraceptive effect could also be completely reversed voluntarily at any time by immunoneutralization of antibodies using intravaginal administration of the peptide. Thus, the novel synthetic YLP(12) peptide is an attractive candidate for contraceptive vaccine development, and diagnosis and treatment of immunoinfertility in humans.

Acrosome Reaction↗
PubMed2004

Efficacy of oral micronized progesterone when applied via vaginal route.

The aim of the study was to compare the efficacy of oral micronized progesterone when applied by the vaginal route. The comparative study of serum progesterone levels between oral and vaginal micronized progesterone administration was conducted in sixty female volunteers. The subjects were equally divided into two groups to receive the drug either via the oral or vaginal route. The subjects' profiles showed that there was no significant difference in general characteristics between these two groups. The blood tests for estrogen and progesterone levels were performed on all volunteers before and after the drug administration. The data collected from the experiment revealed that the serum progesterone levels achieved by oral administration (5.06 +/- 2.95 ng/ml) differed significantly (p < 0.001) from those achieved by vaginal administration (8.26 +/- 4.09 ng/ml). The data also revealed that the serum progesterone levels of the oral administration group (4.23 +/- 2.68 ng/ml) did not differ significantly (p = 0.925) from the other group (4.15 +/- 3.40 ng/ml) when the serum estrogen level was less than 30 pg/ml. On the contrary, when the serum estrogen level was at least 30 pg/ml, there was a significant (p < 0.005) difference in the serum progesterone levels between these two groups (6.32 +/- 2.99 ng/ml for the oral route and 9.76 +/- 3.23 ng/ml for the vaginal route).

Administration, Intravaginal↗
PubMed2004

Management of vaginitis.

Common infectious forms of vaginitis include bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis. Vaginitis also can occur because of atrophic changes. Bacterial vaginosis is caused by proliferation of Gardnerella vaginalis, Mycoplasma hominis, and anaerobes. The diagnosis is based primarily on the Amsel criteria (milky discharge, pH greater than 4.5, positive whiff test, clue cells in a wet-mount preparation). The standard treatment is oral metronidazole in a dosage of 500 mg twice daily for seven days. Vulvovaginal candidiasis can be difficult to diagnose because characteristic signs and symptoms (thick, white discharge, dysuria, vulvovaginal pruritus and swelling) are not specific for the infection. Diagnosis should rely on microscopic examination of a sample from the lateral vaginal wall (10 to 20 percent potassium hydroxide preparation). Cultures are helpful in women with recurrent or complicated vulvovaginal candidiasis, because species other than Candida albicans (e.g., Candida glabrata, Candida tropicalis) may be present. Topical azole and oral fluconazole are equally efficacious in the management of uncomplicated vulvovaginal candidiasis, but a more extensive regimen may be required for complicated infections. Trichomoniasis may cause a foul-smelling, frothy discharge and, in most affected women, vaginal inflammatory changes. Culture and DNA probe testing are useful in diagnosing the infection; examinations of wet-mount preparations have a high false-negative rate. The standard treatment for trichomoniasis is a single 2-g oral dose of metronidazole. Atrophic vaginitis results from estrogen deficiency. Treatment with topical estrogen is effective.

Administration, Intravaginal↗
PubMed2004

[Hydrogels: properties and application in the technology of drug form. II. Possibilities of use of hydrogels as active substance carriers].

In first unit of running was described the properties, method the obtention and kinds sensitive on factors such how the temperature, pH, the electrolytes, the chosen substances, light, of hydrogels and hydrogel delivery systems. The following study is a review of literature related to application of hydrogel as healing substances carriers, possibility of application of hydrogels in oral, applied on skin and the rectal, vaginal systems of release, applied on nasal as well as passed to eyes and parenteral. The utilization the hydrogels in construction the new systems of release the substance allows to remain the aspect ratio time of substance at the application place, the obtainment of prolonged release the medicine, by parallel of applied dose and the system undesirable effects. The hydrogels on the basis of were received the form of medicine about controlled release the substance, bioadhesive drug carriers as well targetable devices of therapeutic agents.

Administration, Cutaneous↗
PubMed2005

[Medical abortion using methotrexate and misoprostol. Efficacy and tolerability].

UNLABELLED: Medical abortion means interruption of early pregnancy (usually before 9-th gestational week) as a result of administration of abortifacient drugs without surgical intervention. OBJECTIVE: To investigate the efficacy and tolerability of methotrexate plus misoprostol regimen as a method for early medical abortion < 49 days L.M.P. MATERIAL AND METHOD: 50 mg methotrexate was administered orally to 20 women < 49 days L.M.P. followed by 800 mcg misoprostol vaginal and oral administration 3-7 days after the methotrexate. RESULTS: 19 Successful medical abortions (95%). One woman chose vacuum aspiration for termination of the abortion on day 3 of the induced bleeding. No serious side effects were observed after administration of the drugs. CONCLUSION: Medical abortion with methotrexate and misoprostol is safe and effective and can be offered to practicing gynecologists.

Abortifacient Agents, Nonsteroidal↗
PubMed2005

[Treatment of recurrent vulvovaginal candidosis with mycosyst (fluconazole)].

The authors treat 15 women with recurrent vulvovaginal candidosis with 3 sequential oral 150-mg doses of fluconazole (Mycosys, Gedeon Richter), each dose administered 72 hours after the first dose. Candida albicans was isolated in 14 women and Candida glabrata--in one. 14 days later all women had no clinical signs of vulvovaginal candidosis. Three months after the treatment only 11 women consulted for a checking exam--and all of them without clinical complaints, though in three of them (73.3%) C. albicans was isolated from the vaginal discharge. The authors discuss the difficulties in the treatment of recurrent vulvovaginal candidosis and the advantages of the sequential type of therapy with fluconazole.

Administration, Intravaginal↗
PubMed2005

The impact of luteal supplement on pregnancy outcome following stimulated IVF cycles.

This is a prospeve randomised study designed to clarify the impact of various luteal support regimes (HCG and progesterone) on progesterone profiles and pregnancy outcomes. This study involved subjects undergone down regulated. stimulated IVF cycles using various types of luteal support, namely: Cyclogest (n=35). Crinone gel (n=36), various doses of Utrogestan (n=55) and HCG (n=35). Various doses of Utrogestan (administered vaginally), Crinone gel (progesterone administered vaginally) and Cyclogest (progesterone administered rectally) supplementation induced similar end plasma progesterone concentrations ranging from 26 to 32 mmnl/l. These progesterone regimes produced no significant differences. Hence, the impact of exogenous proge,terone supplement was relatively trivial and did not 'stabilise' the sub-optimal luteal phase. In contrast, two small HCG injections during the early and mid-luteal phase possessed a much greater ability to 'stabilise' progesterone profiles. Despite this additional advantage, implantation and pregnancy rates with either HCG or progesterone supplements were similar. Although none of these forms of luteal support adequately 'normalised' luteal progesterone profiles, this did not appear to be detrimental to the process of implantation.

Administration, Intravaginal↗
PubMed2005

Comparison or oral versus vaginal misoprostol & continued use of misoprostol after mifepristone for early medical abortion.

BACKGROUND & OBJECTIVE: Medical abortion though legalized in India, is still not very popular. A disadvantage of medical abortion is the longer duration of bleeding compared with surgical abortion which may reduce acceptability. Due consideration needs to be given to the issues related to medical abortion for improving the reproductive health status of women suffering from consequences of unsafe and illegal surgical abortion. The present study compared the efficacy of oral and vaginal administration of misoprostol after a single dose of 200 mg of mifepristone and evaluated the influence of continuing misoprostol for one week on efficacy and side effects. METHODS: A double-blind randomized controlled trial with 150 healthy pregnant women requesting medical abortion with < 63 days of amenorrhoea was conducted in the gynecological and family planning clinic at All India Institute of Medical Sciences, New Delhi. Mifepristone (200 mg) was administered orally on day one, followed by 0.8 mg misoprostol either orally or vaginally on day three. Women in the oral group and one of the two vaginal groups continued 0.4 mg of oral misoprostol twice daily for seven days. RESULTS: Complete abortion rate in each of the groups was 96-100 per cent. The addition of misoprostol 0.4 mg twice a day from day 4-10 did not help in increasing successful outcome or shortening of duration or amount of bleeding. INTERPRETATION & CONCLUSION: Medical abortion for pregnancy up to 63 days using misoprostol 0.8 mg vaginal/oral after pretreatment with mifepristone 200 mg is a safe and successful procedure. No differences in efficacy or duration of bleeding were observed with addition of oral misoprostol for 1 wk after abortion.

Abortifacient Agents, Nonsteroidal↗
PubMedDate not supplied

[Study of vaginal and intestinal microflora of women in the prenatal period and its correction in dysbacteriosis].

A comparative research of the structure of vaginal and intestinal microflora in norm and at kidney pathologies in women in the prenatal period was carried out. At physiologically normal course of pregnancy microbiocenosis of vagina and intestine does not contain pathogenic and conditional-pathogenic microorganisms. Lactic acid bacteria are fixed within the limits of 10(5)-10(8) CFU/1 ml in the vagina secretion and 10(7)-10(8) CFU/1 g in the intestine content. The spore microorganisms have completely disappeared in vaginal biocenosis of women with pyelonephritis after pharmacotherapy; and colibacterias has disappeared in 62% of women. Quantity of lactic acid bacteria has also decreased. Quantity of E. coli (10(8)- 10(9)) CFU/g, sporous microorganisms (10(3)-10(4)) CFU/g and yeast (10(4)-10(5)) CFU/g has considerably increased in the content of intestine. Lactic acid bacteria in content of the vagina are presented by: Lactobacillus acidophilus, L. plantarum, L. fermentum, L. vaginalis; in content of the intestine--L. plantarum and L. fermentum. All the isolated strains of lactobacilli are resistant to metrogyl and amphotericin, 87%--to cephoxitine, cypropfloxacine. Twenty three of 24 strains of lactic acid bacteria--antagonists of pathogenic microflora have shown adhesion to vaginal epthelium. The degree of adhesive activity depends on the strain and genus specificity of cultures. The highest index of adhesiveness in indicated in Enterococcus faecium (5.82 - 7.62) and Streptococcus salivarius subsp. thermophilus (2.74 - 6.40) strains. The screening of strains has been performed, which suppress growth of gas-producing microflora. The strain of Lactobacillus plantarum 200D proved to be the most active one. A complex of cultures of the lactic bacteria providing normalization of microbial cenosis of the vagina in women in the prenatal period has been selected as based on the data obtained. The biotechnology of production of vaginal suppositories is developed.

Administration, Intravaginal↗
PubMed2006

Medical abortion in late second trimester--a comparative study with misoprostol through vaginal versus oral followed by vaginal route.

A randomised controlled trial was conducted to compare the relative efficacies of two regimens: Misoprostol given only vaginally or orally followed by vaginal administration of the same drug, for second trimester abortion. Multiparous women with a pregnancy of 16 to 20 weeks with no contra-indications to the drug were selected. They were randomly allocated into two groups. Patients in the first group, the 'only vaginal misoprostol' group (n = 30), were given misoprostol 400 microg 6 hourly only through vaginal route up to a maximum of 4 such doses. Women in the other group, the 'oral plus vaginal misoprostol' group (n = 24), received 400 microg of the drug at intervals of 12 hours for 2 doses, followed by 400 microg 6 hourly per vaginum up to a maximum of 4 such. Ten units of oxytocin was started in all cases when os was 4 cm dilated. Complete expulsion was 83.33% with an average time of 13.28 hours in the only vaginal misoprostol group. Complete expulsion occurred in 87.5% of women receiving oral followed by vaginal misoprostol with an average time of 8.93 +/- 0.01 hours from the first vaginal dose (p<0.05). More importantly, 66.67% women in second group delivered within 10 hours of the vaginal dose. Complete expulsion was defined in those cases where no check curettage was needed. Side-effects were not significant. This implies that misoprostol given by the vaginal route following oral priming doses had a higher success rate and a potential for a reduced hospital stay and higher bed turn-over rate.

Abortifacient Agents, Nonsteroidal↗
PubMed2006

Tailor made.

Explore the source record for details and available documents.

Administration, Cutaneous↗
PubMed1991

Comparison of topical fungicides in women suffering from vulvovaginitis.

The effects of Nizoral cream and clotrimazole ointment have been compared under identical experimental conditions in 35 resp. 37 women suffering from mycotic vulvovaginitis. Nizoral tablet was administered as a basic therapy. Significant differences were not observed when comparing the results of the different 10-day long adjuvant therapies. Considering therapeutic action Nizoral cream was found to be equivalent to the successfully used clotrimazole ointment.

Administration, Intravaginal↗